April 24, 2013
/PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in
, today announced that it has donated 500 bottles of human albumin and 1000 bottles of Tetanus immunoglobulin through its Shandong Taibang subsidiary for those injured in the devastating earthquake that struck Lushan County, Ya'an City located in
April 21, 2013
. The donation will be delivered immediately through the Shandong Provincial Health Bureau to the ravaged area.
David (Xiaoying) Gao
, Chairman & Chief Executive Officer of China Biologic, commented, "As a leading plasma-based biopharmaceutical company in
, it is part of our corporate social responsibility policy to help Chinese citizens, particularly during times of extreme need. We extend our condolences and thoughts to any families who have suffered through this tragedy and wish for a prompt recovery for the people in this quake-hit region."
About China Biologic Products, Inc.
China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in
. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in
and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in
. For additional information, please see the Company's website
Safe Harbor Statement
This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.